Multisystem Inflammatory Syndrome in Children in Western Countries? Decreasing Incidence as the Pandemic Progresses?: An Observational Multicenter International Cross-sectional Study.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
15
9
2022
medline:
18
11
2022
entrez:
14
9
2022
Statut:
ppublish
Résumé
SARS-CoV-2 variations as well as immune protection after previous infections and/or vaccination may have altered the incidence of multisystemic inflammatory syndrome in children (MIS-C). We aimed to report an international time-series analysis of the incidence of MIS-C to determine if there was a shift in the regions or countries included into the study. This is a multicenter, international, cross-sectional study. We collected the MIS-C incidence from the participant regions and countries for the period July 2020 to November 2021. We assessed the ratio between MIS-C cases and COVID-19 pediatric cases in children <18 years diagnosed 4 weeks earlier (average time for the temporal association observed in this disease) for the study period. We performed a binomial regression analysis for 8 participating sites [Bogotá (Colombia), Chile, Costa Rica, Lazio (Italy), Mexico DF, Panama, The Netherlands and Catalonia (Spain)]. We included 904 cases of MIS-C, among a reference population of 17,906,432 children. We estimated a global significant decrease trend ratio in MIS-C cases/COVID-19 diagnosed cases in the previous month ( P < 0.001). When analyzing separately each of the sites, Chile and The Netherlands maintained a significant decrease trend ( P < 0.001), but this ratio was not statistically significant for the rest of sites. To our knowledge, this is the first international study describing a global reduction in the trend of the MIS-C incidence during the pandemic. COVID-19 vaccination and other factors possibly linked to the virus itself and/or community transmission may have played a role in preventing new MIS-C cases.
Sections du résumé
BACKGROUND
SARS-CoV-2 variations as well as immune protection after previous infections and/or vaccination may have altered the incidence of multisystemic inflammatory syndrome in children (MIS-C). We aimed to report an international time-series analysis of the incidence of MIS-C to determine if there was a shift in the regions or countries included into the study.
METHODS
This is a multicenter, international, cross-sectional study. We collected the MIS-C incidence from the participant regions and countries for the period July 2020 to November 2021. We assessed the ratio between MIS-C cases and COVID-19 pediatric cases in children <18 years diagnosed 4 weeks earlier (average time for the temporal association observed in this disease) for the study period. We performed a binomial regression analysis for 8 participating sites [Bogotá (Colombia), Chile, Costa Rica, Lazio (Italy), Mexico DF, Panama, The Netherlands and Catalonia (Spain)].
RESULTS
We included 904 cases of MIS-C, among a reference population of 17,906,432 children. We estimated a global significant decrease trend ratio in MIS-C cases/COVID-19 diagnosed cases in the previous month ( P < 0.001). When analyzing separately each of the sites, Chile and The Netherlands maintained a significant decrease trend ( P < 0.001), but this ratio was not statistically significant for the rest of sites.
CONCLUSIONS
To our knowledge, this is the first international study describing a global reduction in the trend of the MIS-C incidence during the pandemic. COVID-19 vaccination and other factors possibly linked to the virus itself and/or community transmission may have played a role in preventing new MIS-C cases.
Identifiants
pubmed: 36102705
doi: 10.1097/INF.0000000000003713
pii: 00006454-202212000-00012
pmc: PMC9645445
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-993Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
A.S.-A. is working as a consultant in the Paediatric Infectious Diseases and Immunodeficiencies Unit at Hospital Universitari Vall d’Hebron (Barcelona, Catalonia, Spain), and is the coordinator of the research network for COVID-19 in children in Catalonia (COPEDI-CAT). The other authors have no funding or conflicts of interest to disclose.
Références
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–346.
Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325:1074–1087.
Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347–358.
García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020;24:666.
Lima-Setta F, Magalhães-Barbosa MC, Rodrigues-Santos G, et al. Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study. J Pediatr (Rio J). 2021;97:354–361.
Moraleda C, Serna-Pascual M, Soriano-Arandes A, et al. Multi-inflammatory syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Spain. Clin Infect Dis. 2021;72:e397–e401.
Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20:e276–e288.
Centers for Disease Control and Prevention Health Alert Network (HAN). Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Available from: https://emergency.cdc.gov/han/2020/han00432.asp . Accessed September 3, 2022.
Royal College of Paediatrics and Child Health. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians, 2020. Available from: https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance
Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2021;5:133–141.
World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific Brief. 2020. Available from: https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19 . Accessed September 3, 2022.
McArdle AJ, Vito O, Patel H, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385:11–22.
Schlapbach LJ, Andre MC, Grazioli S, et al. Best practice recommendations for the diagnosis and management of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS; multisystem inflammatory syndrome in children, MIS-C) in Switzerland. Front Pediatr. 2021;9:667507.
Farooqi KM, Chan A, Weller RJ, et al. Longitudinal outcomes for multisystem inflammatory syndrome in children. Pediatrics. 2021;148:e2021051155.
Ravichandran S, Tang J, Grubbs G, et al. SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19. Nat Immunol. 2021;22:1452–1464.
Koskela U, Helve O, Sarvikivi E, Helminen M, Nieminen T, Peltola V, Renko M, Saxén H, Pasma H, Pokka T, Honkila M, Tapiainen T. Multi-inflammatory syndrome and Kawasaki disease in children during the COVID-19 pandemic: a nationwide register-based study and time series analysis. Acta Paediatr. 2021;110:3063–3068.
Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17:731–748.
Munro APS, Faust SN. COVID-19 in children: current evidence and key questions. Curr Opin Infect Dis. 2020;33:540–547.
Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175:143–156.
Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open. 2021;4:e2116420.
Dionne A, Son MBF, Randolph AG. An update on multisystem inflammatory syndrome in children related to SARS-CoV-2. Pediatr Infect Dis J. 2022;41:e6–e9.
Dobson A. J. An Introduction to Generalized Linear Models. Chapman & Hall, 1990. Available from: https://uk.mathworks.com/help/stats/glmfit.html . Accessed September 3, 2022.
Perramon A, Soriano-Arandes A, Pino D, et al. Schools as a framework for COVID-19 epidemiological surveillance of children in Catalonia, Spain: a population-based study. Front Pediatr. 2021;9:754744.
Fang SF, Liu N, Du HW. BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:1.
Calendario de vacunación masiva contra COVID-19, Ministerio de Salud de Chile, 2022. Available from: https://www.minsal.cl/calendario-de-vacunacion-masiva-contra-covid-19/ . Accessed February 1, 2022.
Figures in the COVID-19 vaccination programme. Dutch National Institute for Public Health and the Environment. Ministry of Health, Welfare and Sport, The Netherlands. 2022. Available from: https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme . Accessed February 1, 2022.
Levy M, Recher M, Hubert H, et al. multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327:281–283.
Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years—United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71:52–58.
Brodin P. SARS-CoV-2 infections in children: understanding diverse outcomes. Immunity. 2022;55:201–209.
Lee S, Yoon GY, Myoung J, et al. Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells. Emerg Microbes Infect. 2020 Dec;9:2169–2179.
Yonker LM, Gilboa T, Ogata AF, et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. 2021;131:e149633.
Buonsenso D, Riitano F, Valentini P. Pediatric inflammatory multisystem syndrome temporally related with SARS-CoV-2: Immunological similarities with acute rheumatic fever and toxic shock syndrome. Front Pediatr. 2020;8:574.
Kissler SM, Fauver JR, Mack C, et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. N Engl J Med. 2021;385:2489–2491.
Noval Rivas M, Porritt RA, Cheng MH, et al. Multisystem inflammatory syndrome in children and long COVID: the SARS-CoV-2 viral superantigen hypothesis. Front Immunol. 2022;13:941009.